Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2025-06-06 00:00:00 ET · period of report 2025-06-05 · accession 0000950170-25-083321 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-06 | 2025-06-05 | XENE | GANNON STEVEN | Dir | S - Sale | $30.48 | -3 | 7,141 | -0.0% | -$91.44 |
| DM | 2025-06-06 | 2025-06-05 | XENE | GANNON STEVEN | Dir | A - Grant | $0.00 | +19.7K | 2,645 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-06-05 | S | D | 3 | $30.48 | 7,141 | D | — | — | (F1) Shares automatically sold in payment of transfer fee for transfer of shares to an alternate brokerage account. |
| 2 | Derivative | Share Option (Right to Buy) | 2025-06-05 | A | A | 17,012 | $0.00 | 17,012 | D | $30.73 · — to 2035-06-04 | 17,012 Common Shares | (F2) Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. |
| 3 | Derivative | Restricted Share Units | 2025-06-05 | A | A | 2,645 | $0.00 | 2,645 | D | $0.00 · — to — | 2,645 Common Shares | (F3) Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. |